Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2026 08:58 ET | Source: Research and Markets

Danyelza (Y-mAbs Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Danyelza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
March 10, 2026 08:21 ET | Source: Research and Markets

Evkeeza (Regeneron) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Evkeeza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
March 10, 2026 06:50 ET | Source: Research and Markets

Lamzede (Chiesi Farmaceutici) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Lamzede Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
March 09, 2026 12:25 ET | Source: Research and Markets

Iplex (Insmed: mecasermin rinfabate) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Iplex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
February 17, 2026 11:32 ET | Source: Research and Markets

U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs

Dublin, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The "U.S. Orphan Drug Market, Drug Sales, Price, Dosage & Clinical Pipeline Insight 2031" drug pipelines has been added to ResearchAndMarkets.com's...
February 04, 2026 10:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

Dewpoint doses first patient in Phase 1a/2a trial of DPTX3186, an FDA Fast Track, Orphan-designated beta-catenin modulator for advanced solid tumors.
January 22, 2026 06:40 ET | Source: Research and Markets

Global Orphan Drugs Market to Surpass USD 443 Billion by 2031 Driven by Advances in Genomics and Precision Medicine

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Orphan Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
January 21, 2026 15:00 ET | Source: BPGbio

UPDATE - BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency

BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has...
January 20, 2026 07:00 ET | Source: BPGbio

BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency

BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has...
December 12, 2025 04:01 ET | Source: Research and Markets

2 Day Virtual FDA (Food and Drug Administration) Drug Approval Process Training Course (Feb 23rd - Feb 24th, 2026)

Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course (Feb 23rd - Feb 24th, 2026)" training has been added to ...